Septerna (SEPN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$98.9M

Revenue (quarter)

$26.7M

Revenue growth (year over year)

+22375.63%

Gross profit (trailing twelve months)

$98.9M

Gross margin

100.00%

Net income (trailing twelve months)

−$24.2M

Net income (quarter)

−$13.0M

Net income growth (year over year)

+47.52%

Net margin

−24.51%

Return on equity

−6.34%

EPS (trailing twelve months)

−$0.53

Book value per share

$8.47

P/E (trailing twelve months)

—

Price to book

4.29

Debt to assets

31.76%

Payout ratio

—

Dividend yield

—

Company profile

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

• Is Septerna (SEPN) profitable?

  No. Septerna reported a net loss of $24.2M over the trailing twelve months.

• How much revenue does Septerna (SEPN) make?

  Septerna generated $98.9M in revenue over the trailing twelve months, up 22375.63% year over year.

• How do I buy stock in Septerna (SEPN)?

  SEPN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.